Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 309

The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.

Noninvasive proteomic biomarkers for alcohol-related liver disease

Open access
Niu, Lili, Thiele, Maja, Geyer, Philipp E., Rasmussen, Ditlev Nytoft, Webel, Henry Emanuel, Santos, Alberto, Gupta, Rajat, Meier, Florian, Strauss, Maximilian, Kjaergaard, Maria, Lindvig, Katrine, Jacobsen, Suganya, Rasmussen, Simon, Hansen, Torben, Krag, Aleksander, Mann, Matthias·2022·Nature Medicine

Abstract

Alcohol-related liver disease (ALD) is a major cause of liver-related death worldwide, yet understanding of the three key pathological features of the disease—fibrosis, inflammation and steatosis—remains incomplete. Here, we present a paired liver–plasma proteomics approach to infer molecular pathophysiology and to explore the diagnostic and prognostic capability of plasma proteomics in 596 individuals (137 controls and 459 individuals with ALD), 360 of whom had biopsy-based histological assessment. We analyzed all plasma samples and 79 liver biopsies using a mass spectrometry (MS)-based proteomics workflow with short gradient times and an enhanced, data-independent acquisition scheme in only 3 weeks of measurement time. In plasma and liver biopsy tissues, metabolic functions were downregulated whereas fibrosis-associated signaling and immune responses were upregulated. Machine learning models identified proteomics biomarker panels that detected significant fibrosis (receiver operating characteristic–area under the curve (ROC–AUC), 0.92, accuracy, 0.82) and mild inflammation (ROC–AUC, 0.87, accuracy, 0.79) more accurately than existing clinical assays (DeLong’s test, P < 0.05). These biomarker panels were found to be accurate in prediction of future liver-related events and all-cause mortality, with a Harrell’s C-index of 0.90 and 0.79, respectively. An independent validation cohort reproduced the diagnostic model performance, laying the foundation for routine MS-based liver disease testing.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01850-y

Cites

63 of 63 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 63 references

Cited by

See all 309

Metadata

Authors
Niu, L., Thiele, M., Geyer, P. E., Rasmussen, D. N., Webel, H. E., Santos, A., Gupta, R., Meier, F., Strauss, M., Kjaergaard, M., Lindvig, K., Jacobsen, S., Rasmussen, S., Hansen, T., Krag, A., & Mann, M.
Venue
Nature Medicine
Published
2022-06
Volume
28
Issue
6
Pages
1277-1287
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4281877108
Cited by
309
References
63
FWCI
35.65
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Noninvasive proteomic biomarkers for alcohol-related liver disease. https://app.cochat.ai/papers/10.1038/s41591-022-01850-y
The paper
Niu, L., Thiele, M., Geyer, P. E., Rasmussen, D. N., Webel, H. E., Santos, A., Gupta, R., Meier, F., Strauss, M., Kjaergaard, M., Lindvig, K., Jacobsen, S., Rasmussen, S., Hansen, T., Krag, A., & Mann, M. (2022). Noninvasive proteomic biomarkers for alcohol-related liver disease. Nature Medicine. https://doi.org/10.1038/s41591-022-01850-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.